在疫苗安全数据链中利用近实时监测与基于树的数据挖掘评估老年人呼吸道合胞病毒疫苗的安全性
在美国疫苗安全数据链(VSD)中对≥60岁成人开展两项互补性上市后安全性评估:快速周期分析纳入436823名接种者,基于树的数据挖掘纳入248056名接种者。快速周期分析12项预设结局中11项无统计学信号,Arexvy后免疫性血小板减少性紫癜出现信号但病历复核后未确认关联;数据挖掘未发现两种疫苗的任何统计学显著聚集。结论认为这些上市后安全性评估提供了支持老年人RSV疫苗安全性的证据,并指出随数据积累需对罕见不良事件继续监测。
要点
- 快速周期分析纳入436823名RSV疫苗接种者,12项预设结局中11项无统计学信号。
- Arexvy后免疫性血小板减少性紫癜出现信号,病历复核后未确认关联。
- 基于树的数据挖掘纳入248056名接种者,两种疫苗均未发现统计学显著聚集。
核心结论
- 这些上市后安全性评估提供了支持老年人RSV疫苗安全性的证据。
- 随着更多数据积累,需要对罕见不良事件进行额外监测。
研究设计与样本
- 快速周期分析采用序贯队列设计,对近实时数据进行每两周一次的分析,比较接种后两个风险间期(1-21天、1-42天)与对照间期12项预设结局的发生率,监测期为2023年8月1日至2024年9月28日,13个VSD站点中9个参与。
- 基于树的数据挖掘采用自身对照设计,旨在识别接种后1-56天住院或急诊环境中ICD-10诊断编码的时间聚集,不预设结局或风险间期,研究期为2023年7月1日至2023年12月31日,10个站点参与。
- 快速周期分析纳入436823名接种RSV疫苗者;基于树的数据挖掘纳入248056名接种者。
主要发现
- 快速周期分析中,12项不良事件里11项未发现统计学信号。
- Arexvy后免疫性血小板减少性紫癜检测到信号,但病历复核后的再分析未确认该关联。
- 基于树的数据挖掘识别出3429个诊断编码的53734条计数,两种疫苗均未发现统计学显著聚集。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出,随着更多数据积累,需要对罕见不良事件进行额外监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Two respiratory syncytial virus (RSV) vaccines, Pfizer's Abrysvo and GSK's Arexvy, were licensed in 2023 in the U.S. However, population-based assessments of their safety in adults ≥60 years have not been widely published. We provide results from two complementary investigations of vaccinated adults in the Vaccine Safety Datalink (VSD). METHODS: The rapid cycle analysis (RCA) used a sequential cohort design and biweekly analyses of near real-time data to compare the incidence of 12 pre-specified outcomes in two post-vaccination risk intervals (1-21, 1-42 days) with the incidence in comparison intervals. The surveillance period was August 1, 2023, through September 28, 2024; nine of 13 VSD sites participated. Statistically significant signals were investigated by medical record review with re-analysis of confirmed outcomes. The self-controlled tree-based data mining analysis was designed to identify temporal clustering of ICD-10 diagnosis codes in the inpatient or emergency department settings 1-56 days post-vaccination, without pre-specifying outcomes or risk intervals. The study period was July 1, 2023, through December 31, 2023; 10 sites participated. RESULTS: The RCA analysis included 436,823 persons who received an RSV vaccine. No statistical signal was identified for 11 of 12 adverse events. A signal was detected for immune thrombocytopenic purpura following Arexvy, but re-analysis following medical record review did not confirm an association. The tree-based data mining analysis included 248,056 vaccinees, identified 53,734 counts of 3429 diagnosis codes, and identified no statistically significant clusters for either vaccine. CONCLUSIONS: These post-licensure safety assessments provide evidence supporting the safety of RSV vaccines in older adults. As more data accrue, additional monitoring is warranted for rare adverse events.
引用
- Donahue JG, Cocoros NM, Kieke BA, et al. Near real-time surveillance and tree-based data mining to assess the safety of respiratory syncytial virus vaccines in older adults in the vaccine safety datalink. Vaccine. 2025. PMID: 41138438. doi:10.1016/j.vaccine.2025.127873
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。